One of the first studies on NPs was published in 2011 and focused on the usage of EGFR-targeted heparin-cis-diamminedichloroplatinum (II) (EHDDP) NPs for the delivery of ChT to the tumor site in NSCLC. Here, EGFR is linked to neoplasm.